Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmatrix (PULM) reported third-quarter 2026 financial results and advanced its proposed merger with Eos SENOLYTIX, which it expects to close by year-end. The merger registration statement is effective and stockholders have approved the transaction. Closing still requires Nasdaq listing approval and completion of an approved reverse stock split. Eos would become the combined company's business.
Third-quarter net loss was $1.213 million, versus $877,000 a year earlier; loss per common share widened to $0.34 from $0.24. General and administrative expenses rose to $1.220 million from $858,000, primarily reflecting merger-related work. Cash and equivalents fell to $1.398 million from $4.088 million at December 31, 2025; another $700,000 was restricted. Pulmatrix expects available cash to fund operations at least through the anticipated merger closing. Its clinical development remains on hold while it seeks to license or monetize its assets.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSeries B preferred stock placement with an Eos affiliate raised $1.0 million in gross proceeds. 21% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Eos merger secured stockholder approval and an effective registration statement; Pulmatrix expects closing by year-end.
- Moderate pointNine-month net loss narrowed to $3.421 million from $4.234 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.PUR1900 received Indian regulatory approval for Phase 3; partner Cipla expects initiation in 2026.
- Moderate pointPUR3100 received FDA permission to proceed with a Phase 2 acute migraine study.
10 minor points
- Minor pointNine-month loss per common share narrowed to $0.95 from $1.16 a year earlier.
- Minor pointNine-month administrative expenses declined to $3.553 million from $4.220 million a year earlier.
- Minor pointResearch expenses fell to $1,000 quarterly and $6,000 year-to-date, versus $8,000 and $41,000 respectively.
- Minor pointNine-month other income, net, reached $108,000, versus other expense of $164,000 a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.PUR1900 provides Pulmatrix 2% royalties on potential Cipla net sales outside the United States, conditional on successful commercialization.
- Minor pointPUR3100 Phase 1 showed peak exposure in the targeted therapeutic range and maximum concentration at five minutes.
- Minor pointPUR3100 Phase 1 groups showed less nausea and no vomiting compared with intravenous dihydroergotamine.
- Minor pointPUR1800 Phase 1b results indicated tolerability with no observed safety signals.
- Minor pointPulmatrix received an Indian patent with claims encompassing PUR1900 in July 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pulmatrix plans to license or monetize clinical assets, including pursuing United States PUR1900 opportunities with Cipla.
Negative
- Major pointPulmatrix's clinical development remains on hold while it pursues asset licensing or monetization.
- Major pointSeries B convertible preferred stock issued in the private placement introduces potential common-stock dilution.
- Moderate pointThird-quarter net loss widened to $1.213 million from $877,000 a year earlier.
- Moderate pointCash and equivalents fell to $1.398 million from $4.088 million at December 31, 2025.
- Minor pointMerger closing remains dependent on Nasdaq listing approval and completion of the stockholder-approved reverse split.
8 minor points
- Minor pointThird-quarter loss per common share widened to $0.34 from $0.24 a year earlier.
- Minor pointThird-quarter administrative expenses rose to $1.220 million from $858,000, primarily from merger-related activities.
- Minor point. Forward-looking: it has not happened yet and may not happen.Restricted cash of $700,000 becomes unrestricted after merger consummation or under the merger agreement's terms.
- Minor pointSeries B preferred dividends accrued totaled $21,000 quarterly and $37,000 year-to-date.
- Minor pointInterest income declined to $8,000 quarterly and $30,000 year-to-date, versus $30,000 and $124,000 respectively.
- Minor pointNine-month warrant fair-value adjustment income was zero, versus $67,000 a year earlier.
- Minor pointTotal liabilities increased to $1.017 million from $329,000 at December 31, 2025.
- Minor pointStockholders' equity declined to $1.346 million from $3.810 million at December 31, 2025.
News Explained
The Series B structure may dilute existing holders if preferred shares convert; original placement proceeds went to Pulmatrix, but later resale proceeds do not.
Pulmatrix says its merger with Eos remains proposed, with closing anticipated in
The resale registration covers up to 491,607 common shares issuable on conversion and dividends—about
The registration is effective, so the selling stockholder may resell covered shares; Pulmatrix receives no proceeds from those resales.
As of
For PUR1900, Cipla has approval in India to proceed with a Phase 3 trial and expects to begin in
Sources and calculations
- Pulmatrix third-quarter 2026 results and merger update (2026-11-17)
- S-3/A resale registration record (2026-10-02)
- Pulmatrix third-quarter 2026 fundamentals (2026Q3)
- Dilution (version supplied)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,398,000 / ($770,000 / 92) = 167 days
Key Figures
- General and administrative expenses
- $1.2 million
- Three months ended September 30, 2026; compared with $0.9 million in 2025
- Net loss
- $1.213 million
- Three months ended September 30, 2026; compared with $0.877 million in 2025
- Research and development expenses
- Less than $0.1 million
- Three months ended September 30, 2026 and 2025
- Cash and cash equivalents
- $1.4 million
- As of September 30, 2026; compared with $4.1 million as of December 31, 2025
- Restricted cash
- $0.7 million
- As of September 30, 2026; would become unrestricted following merger consummation or under the Merger Agreement
- Anticipated merger closing
- November 2026
- Subject to Nasdaq listing approval, completion of the approved reverse stock split, and other customary closing conditions
Previous Acquisition,earnings Reports
-
Filed Form S-4 and anticipated merger closing in the third quarter, subject to customary conditions.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form s-4 regulatory
convertible preferred stock financial
going concern financial
investigational new drug regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Merger with Eos SENOLYTIX expected to close by end of the year
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform. To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger. We anticipate closing the proposed merger by the end of the year."
Proposed Merger with Eos SENOLYTIX
As previously reported, on March 26, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") with Eos SENOLYTIX, Inc. ("Eos"), pursuant to which a wholly owned subsidiary of the Company will merge with and into Eos, with Eos surviving as a wholly owned subsidiary of the Company (the "Merger"). The proposed Merger is currently anticipated to close in November 2026, subject to Nasdaq's approval of the listing of the shares of the Company's common stock to be issued in connection with the Merger, the completion of the reverse stock split approved by the Company's stockholders on October 26, 2026, and other customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company.
In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of
Additional information about the Merger Agreement was previously disclosed in a registration statement on Form S-4 (File No. 333-297342) initially filed with the Securities and Exchange Commission (the "SEC") on July 9, 2026, as amended, and declared effective on September 25, 2026.
Pulmatrix Seeks to Out-license or Monetize its Clinical Assets
iSPERSE™ Technology
- iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases.
- As of September 30, 2026, Pulmatrix's patent portfolio related to iSPERSE™ included approximately 143 granted patents, 17 of which are
U.S .-granted patents, plus approximately 47 pending patent applications in theU.S . and other jurisdictions. - In July 2026, Pulmatrix was awarded a patent in
India with claims encompassing PUR1900 resulting from a patent hearing inIndia .
PUR1900
- PUR1900, has been approved to proceed to a Phase 3 in
India conducted by our partner Cipla. This is the Company's inhaled iSPERSE™ formulation of the antifungal drug itraconazole being investigated for various indications. The Company and its partner, Cipla, wound down a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development outsidethe United States , and completed their Phase 2 study inIndia , published positive results and has been approved byIndia's Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026. - Pulmatrix will receive
2% royalties on any potential future net sales by Cipla outsidethe United States should Cipla successfully market PUR1900 outsidethe United States . Withinthe United States , the Company and Cipla will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need.
PUR3100
- PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine ("DHE") engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.
- The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously ("IV") administered DHE dose group.
PUR1800
- PUR1800 is a Narrow Spectrum Kinase Inhibitor ("NSKI"), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease ("AECOPD"). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.
- In 2024, Pulmatrix published an abstract titled "Ex vivo evaluation of the potential for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis".
Third Quarter 2026 Financial Results
Research and development expenses were less than
General and administrative expenses increased approximately
The Company's total cash and cash equivalents balance as of September 30, 2026, was
|
PULMATRIX, INC. |
|
|||||||
|
Consolidated Balance Sheets |
|
|||||||
|
(in thousands, except share and per share data) |
|
|||||||
|
|
|
|||||||
|
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
|
|
|
(unaudited) |
|
|
|
|
||
|
Assets |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,398 |
|
|
$ |
4,088 |
|
|
Restricted cash |
|
|
700 |
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
258 |
|
|
|
41 |
|
|
Total current assets |
|
|
2,356 |
|
|
|
4,129 |
|
|
Long-term restricted cash |
|
|
7 |
|
|
|
10 |
|
|
Total assets |
|
$ |
2,363 |
|
|
$ |
4,139 |
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
815 |
|
|
$ |
272 |
|
|
Accrued expenses and other current liabilities |
|
|
202 |
|
|
|
57 |
|
|
Total current liabilities |
|
|
1,017 |
|
|
|
329 |
|
|
Total liabilities |
|
|
1,017 |
|
|
|
329 |
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Preferred stock, 6,746 shares designated Series A Convertible Preferred Stock: no 1,100 shares designated Series B Convertible Preferred Stock: |
|
|
987 |
|
|
|
- |
|
|
Common stock, |
|
|
- |
|
|
|
- |
|
|
Additional paid-in capital |
|
|
306,098 |
|
|
|
306,128 |
|
|
Accumulated deficit |
|
|
(305,739) |
|
|
|
(302,318) |
|
|
Total stockholders' equity |
|
|
1,346 |
|
|
|
3,810 |
|
|
Total liabilities and stockholders' equity |
|
$ |
2,363 |
|
|
$ |
4,139 |
|
|
|
|
|
|
|
|
|
|
|
|
PULMATRIX, INC. |
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
(in thousands, except share and per share data) |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
1 |
|
|
$ |
8 |
|
|
$ |
6 |
|
|
$ |
41 |
|
|
General and administrative |
|
|
1,220 |
|
|
|
858 |
|
|
|
3,553 |
|
|
|
4,220 |
|
|
Total operating expenses |
|
|
1,221 |
|
|
|
866 |
|
|
|
3,559 |
|
|
|
4,261 |
|
|
Loss from operations |
|
|
(1,221) |
|
|
|
(866) |
|
|
|
(3,559) |
|
|
|
(4,261) |
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
8 |
|
|
|
30 |
|
|
|
30 |
|
|
|
124 |
|
|
Fair value adjustment of warrants |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
67 |
|
|
Other income (expense), net |
|
|
- |
|
|
|
(41) |
|
|
|
108 |
|
|
|
(164) |
|
|
Total other income (expense), net |
|
|
8 |
|
|
|
(11) |
|
|
|
138 |
|
|
|
27 |
|
|
Net loss |
|
$ |
(1,213) |
|
|
$ |
(877) |
|
|
$ |
(3,421) |
|
|
$ |
(4,234) |
|
|
Dividends accrued on Series B Convertible Preferred Stock |
|
|
(21) |
|
|
|
- |
|
|
|
(37) |
|
|
|
- |
|
|
Net loss attributable to common stockholders |
|
|
(1,234) |
|
|
|
(877) |
|
|
|
(3,458) |
|
|
|
(4,234) |
|
|
Net loss per share attributable to common stockholders – basic |
|
$ |
(0.34) |
|
|
$ |
(0.24) |
|
|
$ |
(0.95) |
|
|
$ |
(1.16) |
|
|
Weighted average common shares outstanding – basic and diluted |
|
|
3,652,285 |
|
|
|
3,652,285 |
|
|
|
3,652,285 |
|
|
|
3,652,285 |
|
About Pulmatrix, Inc.
Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company's inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html.
About Eos SENOLYTIX, Inc.
Eos SENOLYTIX, based in Houston, Texas, develops MitoXcel geropeptides as FDA-regulated therapeutics for obesity, sarcopenia and other age-related disorders. The Company holds an exclusive license to the MitoXcel platform from its parent company, SENOTHERAPEUTIX, Inc. (f/k/a GEROTHERAPEUTIX), for its therapeutic field. For more information, visit eossenolytix.com.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements other than statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management and include, but are not limited to, the Merger, including the expected timing of closing and the ability to satisfy the remaining closing conditions, including Nasdaq listing approval; the expected Merger-associated financings and the combined company's ability to advance its pipeline through key clinical milestones; the Company's ability to satisfy Nasdaq's Continued Listing Standards; the Company's anticipated cash position following the Merger; and the use of proceeds from the private placement and conversion of the Series B Preferred Stock. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company's ability to divest its clinical assets on terms favorable to the Company, or at all, the Company's ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company's ability to continue as a going concern, the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Eos, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Chuck Padala
Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulmatrix-announces-third-quarter-2026-financial-results-and-progress-on-merger-302941644.html
SOURCE Pulmatrix Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Pulmatrix expect to close its Eos SENOLYTIX merger?
Pulmatrix expects the proposed merger to close by the end of 2026. Stockholders have approved the transaction, and the registration statement is effective. Closing remains subject to Nasdaq approval of the listing of merger shares, completion of the approved reverse stock split and customary closing conditions.
What were Pulmatrix's third-quarter 2026 financial results?
Pulmatrix recorded a $1.213 million net loss, compared with $877,000 in the third quarter of 2025. Loss per common share was $0.34 versus $0.24. General and administrative expenses increased to $1.220 million from $858,000, primarily because of merger-related legal and professional services.
How will the Pulmatrix and Eos SENOLYTIX merger be structured?
A wholly owned Pulmatrix subsidiary will merge into Eos SENOLYTIX, with Eos surviving as a wholly owned Pulmatrix subsidiary. If the transaction closes, Eos's business will continue as the combined company's business.